Key terms
About ELVN
Enliven Therapeutics, Inc. operates as a clinical stage precision oncology company. It is focused on the discovery and development of next-generation small molecule kinase inhibitors and advancing Enliven's pipeline of precision oncology product candidates. The company was founded by Sam S. Kintz, Joe P. Lyssikatos, and Anish Patel in June 2019 and is headquartered in Boulder, CO.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ELVN news
Apr 13
3:28pm ET
Short Report: Bears reduce exposure to Kohlâs as stock momentum fizzles
Apr 11
6:35pm ET
Strong Buy Rating for Enliven Therapeutics’ ELVN-001 Following Outstanding Phase 1 Results and Market Potential
Apr 11
8:04am ET
Enliven announces proof of concept data from Phase 1 trial of ELVN-001
Apr 11
7:45am ET
Enliven to hold a conference call
Apr 11
4:55am ET
Enliven to hold a conference call
Mar 28
4:15pm ET
Enliven to share initial proof of concept data from ELVN-001 Phase 1 trial
Mar 20
7:30am ET
Analysts’ Top Healthcare Picks: Enliven Therapeutics (ELVN), Alphatec Holdings (ATEC)
Mar 19
9:02am ET
Enliven Therapeutics Secures $90M for Clinical Research Expansion
Mar 19
8:40am ET
Enliven announces pipeline updates
Mar 19
8:38am ET
Enliven announces $90M private placement financing
Mar 15
2:55pm ET
Strong Buy Rating for Enliven Therapeutics Backed by Innovative Drug Candidates and Financial Stability
Mar 14
9:45pm ET
TD Cowen Sticks to Their Buy Rating for Enliven Therapeutics (ELVN)
Mar 14
4:23pm ET
Enliven reports Q4 EPS (47c), consensus (54c)
No recent press releases are available for ELVN
ELVN Financials
Key terms
Ad Feedback
ELVN Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ELVN Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
